Ondine Biomedical, Inc. (DE:VF5)
FRANKFURT:VF5
VF5 Stock Chart & Stats
€0.08
<€0.01(2.47%)
At close: 4:00 PM EST
€0.08
<€0.01(2.47%)
Day’s Range― - ―
52-Week Range€0.07 - €0.20
Previous CloseN/A
Volume0.00
Average Volume (3M)580.00
Market Cap
€88.67M
Enterprise Value€109.78M
Total Cash (Recent Filing)€10.58M
Total Debt (Recent Filing)€413.50K
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Sep 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding518,366,940
10 Day Avg. Volume0
30 Day Avg. Volume580
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)21.53
Price to Sales (P/S)28.32
P/FCF Ratio-3.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€139.83K
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthConsistent top-line growth (~18% in 2025) signals improving commercial traction and expanding customer adoption. Durable revenue expansion provides a runway for scale, improving the chance to absorb fixed costs and eventually translate growth into operating leverage if maintained over coming quarters.
Modest Balance-sheet LeverageVery low reported debt relative to equity (debt-to-equity ~0.12) reduces near-term interest burden and provides flexibility to finance the business via equity or modest borrowing. This structural low leverage gives more time to execute strategy before high fixed financing costs constrain operations.
Niche, Structural Market ExposureA focused technology addressing infection prevention in healthcare is a durable structural market: hospitals and providers consistently invest in infection-control solutions. A specialized photodisinfection niche can create technical differentiation and long sales cycles with sticky customers, supporting steady demand.
Bears Say
Severely Deteriorated MarginsA sharp fall in gross margin and an extremely negative net margin indicate the business is not converting revenue into sustainable profit. Structural margin erosion undermines long-term unit economics and means even continued revenue growth may not yield positive operating cash flow without material cost or pricing changes.
Worsening Cash BurnSignificant and accelerating negative operating and free cash flows increase financing risk: cash outflows nearly doubled year-over-year and will force external funding, cost cuts, or strategic shifts unless revenues scale rapidly. Persistent burn limits strategic optionality and raises dilution risk.
Equity Volatility And Funding DependenceHistoric negative equity and sharp declines in shareholders' equity show reliance on capital raises and exposure to dilution. Continued operating losses and cash burn make the capital structure prone to material change, increasing execution risk and potential adverse terms for future financing.
Ondine Biomedical, Inc. News
VF5 FAQ
What was Ondine Biomedical, Inc.’s price range in the past 12 months?
Ondine Biomedical, Inc. lowest stock price was €0.07 and its highest was €0.20 in the past 12 months.
What is Ondine Biomedical, Inc.’s market cap?
Ondine Biomedical, Inc.’s market cap is €88.67M.
When is Ondine Biomedical, Inc.’s upcoming earnings report date?
Ondine Biomedical, Inc.’s upcoming earnings report date is Sep 30, 2026 which is in 97 days.
How were Ondine Biomedical, Inc.’s earnings last quarter?
Ondine Biomedical, Inc. released its earnings results on Jun 04, 2026. The company reported -€0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.022.
Is Ondine Biomedical, Inc. overvalued?
According to Wall Street analysts Ondine Biomedical, Inc.’s price is currently Overvalued.
Does Ondine Biomedical, Inc. pay dividends?
Ondine Biomedical, Inc. does not currently pay dividends.
What is Ondine Biomedical, Inc.’s EPS estimate?
Ondine Biomedical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ondine Biomedical, Inc. have?
Ondine Biomedical, Inc. has 518,366,940 shares outstanding.
What happened to Ondine Biomedical, Inc.’s price movement after its last earnings report?
Ondine Biomedical, Inc. reported an EPS of -€0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.974%.
Which hedge fund is a major shareholder of Ondine Biomedical, Inc.?
Currently, no hedge funds are holding shares in DE:VF5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ondine Biomedical, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth €125.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.62%
12-Months-Change
Fundamentals
Return on Equity
-506.43%
Trailing 12-Months
Asset Growth
9.57%
Trailing 12-Months
Company Description
Ondine Biomedical, Inc.
Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.
Technical Analysis
Avacta Group plc
―
SkinBioTherapeutics
―
4basebio UK Societas
―
Poolbeg Pharma Ltd.
―
Oxford Nanopore Technologies PLC
―
Options Prices
Currently, No data available
---